The CHADS2 versus the New CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: Review of the literature and recommendations for use

Pharmacotherapy

Volumn 32, Issue 3, 2012, Pages 285-296

  Odum, Lauren E ^a   Cochran, Kelly A ^a   Aistrope, Daniel S ^a   Snella, Kathleen A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; CHA 2DS 2 VASc; CHADS 2; Ischemic stroke; Risk stratification; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; FIBRINOLYTIC AGENT;

AGE; AORTA ATHEROSCLEROSIS; BLEEDING RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CLINICAL DECISION MAKING; GENDER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; RISK STRATIFICATION; SCORING SYSTEM; SENESCENCE; SEX DIFFERENCE; VASCULAR DISEASE; COMPARATIVE STUDY; HOSPITALIZATION; PRACTICE GUIDELINE; STANDARD; THROMBOEMBOLISM; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84864586204     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01023.x     Document Type: Review

References (45)

1. American Heart Association. Heart disease and stroke statistics: 2004 update. Dallas, Texas: American Heart Association, 2003.
2. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133:546S-92S.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
4. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269-367.
5. Hart R, Pearce L, McBride R, Rothbart R, Asinger R. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAFI-III clinical trials. Stroke 1999;30:1223-9.
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994;154:1449-57.
7. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003;290:1049-56.
8. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
9. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010;137:263-72.
11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich M, Radford M. Validation of clinical classification schemas for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
12. Lip GYH, Frison L, Haperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemas in an anticoagulated atrial fibrillation cohort. Stroke 2010;41:2731-8.
13. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation. Reduced flow velocity in the left atrial appendage. J Am Soc Echocardiogr 1999;12:1080-7.
14. Hughes M, Lip GYH. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295-304.
15. Marinigh R, Lip GYH, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: Implications for thromboprophylaxis. J Am Coll Cardiol 2010;56:827-37.
16. Hart RG, Pearce LA, Halperin JL, et al.; Stroke Risk in Atrial Fibrillation Work Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39:1901-10.
17. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
18. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemas for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
19. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke 2009;40:1410-6.
20. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score = 1. Thromb Haemost 2010;103:833-40.
21. Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007;370:493-503.
22. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomized controlled trial. Lancet 2003;362:1691-8.
23. Albers GW, Diener HC, Frison L; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatranvs warfarin for stroke prevention in patients with non-valvular atrial fibrillation: A randomized trial. JAMA 2005;293:690-8.
24. van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GYH. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011;9:39-48.
25. Poli D, Lip GYH, Antonucci E, Griofoni E, Lane D. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 2011;22:25-30.
26. The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology 2007;69:546-54.
27. Siu CW, Jim MH, Ho HH, et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: Implications for future risk of ischemic stroke. Chest 2007;132:44-9.
28. Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Intern Med 1990;150:819-21.
29. Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 2004;93:1422-5, A10.
30. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998;128:639-47.
31. Violi F, Lip GYH, Basili S. Peripheral artery disease and atrial fibrillation: A potentially dangerous combination. Intern Emerg Med 2011; June 11 [Epub ahead of print] DOI: 10.1007/s11739-011-0637-0.
32. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005;112: 1687-91.
33. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007;49: 572-7.
34. Harrell E Jr, Califf R, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
35. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 2000;284:876-8.
36. Boriani G, Botto GL, Padeletti L, et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011;42: 1768-70.
37. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457-60.
38. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390-6.
39. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9.
40. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151: 713-9.
41. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HASBLED (Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011;57: 173-80.
42. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-6.
43. Chen WT, White CM, Phung OJ, et al. Association between CHADS2 risk factors and anticoagulation-related bleeding: A systematic review of the literature. Mayo ClinProc 2011;86:509-21.
44. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27:27-30.
45. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRSfocused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:1144-50.